Name: DNTH Insider Trading Activity
Creator: Tracefour
License: https://www.usa.gov/government-works
Keywords: DNTH, insider trading, SEC Form 4, insider transactions

Question 1

How many SEC Form 4 insider filings does DNTH have?

Accepted Answer

Dianthus Therapeutics, Inc. (DNTH) has 21 SEC Form 4 filings (97 transaction rows) in the rolling 365-day window, disclosed by 8 distinct insiders. Most recent filing: Aug 19, 2026.

Question 2

When was the most recent SEC Form 4 filing for DNTH?

Accepted Answer

The most recent Form 4 filing for DNTH on Tracefour is dated Aug 19, 2026.

Question 3

Who is the most active insider at DNTH?

Accepted Answer

The most active SEC Form 4 filer at DNTH in the rolling window is EVP, CFO & CBO Savitz Ryan, with 5 filings.

Question 4

What is the net insider flow at DNTH over the last 6 months?

Accepted Answer

Over the trailing 180 days, insiders at DNTH have net sold $58.4M based on SEC Form 4 disclosures.

Question 5

What is the total insider buy and sell value at DNTH in the current window?

Accepted Answer

Inside the rolling window, insiders at DNTH bought $0 and sold $67.4M based on SEC Form 4 filings.

Question 6

Can I get alerts for DNTH insider trading?

Accepted Answer

Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Dianthus Therapeutics, Inc. (DNTH). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.

						Source
Read Simon	Director	Sale	2,778	$327K	Aug 19	SEC ↗
McGeorge AnneFirst filing	Director	Sale	7,750	$845K	Aug 11	SEC ↗
Read SimonFirst filing	Director	Sale	2,777	$304K	Aug 11	SEC ↗
Veness Adam M	SVP, General Counsel and Sec.	Sale	3,833	$424K	Aug 11	SEC ↗
Veness Adam M	SVP, General Counsel and Sec.	Sale	16,167	$1.8M	Aug 11	SEC ↗
Garcia MarinoFirst in 5 months	CEO AND PRESIDENT	Sale	166,000	$17.9M	Aug 7	SEC ↗
Savitz RyanFirst in 3 months	EVP, CFO & CBO	Sale	31,249	$3.2M	Jul 13	SEC ↗
Veness Adam MFirst filing	SVP, General Counsel and Sec.	Sale	30,000	$2.4M	Jun 18	SEC ↗
Randhawa Simrat	EVP, Head of R&D	Sale	26,530	$2.4M	Jun 2	SEC ↗
Soteropoulos Paula	Director	Sale	599	$51K	May 11	SEC ↗
Savitz Ryan	EVP, CFO & CBO	Sale	8,224	$739K	Apr 10	SEC ↗
Savitz RyanFirst in 4 months	EVP, CFO & CBO	Sale	114,367	$9.5M	Apr 1	SEC ↗
Soteropoulos Paula	Director	Sale	599	$48K	Apr 1	SEC ↗
Soteropoulos PaulaFirst filing	Director	Sale	27,594	$2.2M	Mar 26	SEC ↗
CARR EDWARDFirst filing	CHIEF ACCOUNTING OFFICER	Sale	43,682	$3.6M	Mar 13	SEC ↗
Garcia MarinoFirst filing	CEO AND PRESIDENT	Sale	122,918	$10.0M	Mar 13	SEC ↗
Randhawa SimratFirst in 4 months	EVP, Head of R&D	Sale	33,830	$2.8M	Mar 13	SEC ↗
Savitz Ryan	CFO & CBO	Sale	20,000	$904K	Dec 5	SEC ↗
Randhawa SimratFirst filing	EVP, Head of R&D	Sale	87,507	$3.2M	Nov 14	SEC ↗
Randhawa SimratFirst filing	EVP, Head of R&D	Sale	109,031	$4.2M	Nov 14	SEC ↗
Savitz RyanFirst filing	CFO & CBO	Sale	20,000	$700K	Sep 11	SEC ↗

DNTH

Related companies